Group 1 - The core viewpoint of the article highlights the significant stock price increase of Lepu Biopharma-B (02157), which rose over 6% and is currently trading at 5.64 HKD with a trading volume of 71.31 million HKD [1] - CG Oncology is expected to announce the primary data from the PIVOT-006 Phase 3 clinical trial for cretostimogene monotherapy in high-risk non-muscle invasive bladder cancer in the first half of 2026, which is nearly a year earlier than originally planned due to a faster-than-expected enrollment rate [1] - Lepu Biopharma has exclusive rights to CG0070 injection (Cretostimogene Grenadenorepvec) in Greater China and is actively advancing clinical progress domestically while CG Oncology achieves clinical breakthroughs abroad [1] Group 2 - Lepu Biopharma possesses an already marketed PD-1 antibody, Putili monoclonal antibody, which can complement the treatment of NMIBC (non-muscle invasive bladder cancer) to enhance efficacy through combination therapy [1]
港股异动 | 乐普生物-B(02157)尾盘涨超6% 溶瘤病毒CG0070三期临床提前一年出结果